A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study of investigational agent CFI-402257 in patients with advanced cancer.
The purpose of this study is to see how safe and tolerable CFI-402257 is in cancer patients
as well as the pharmacokinetics (PK). This study is the first time that CFI-402257 is given
to humans.